At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Post-Mkt 02-25 18:43:37 EST
2.44
+0.00
0.00%
盘后2.49
+0.05+2.07%
17:59 EST
High2.63Low2.40Vol60.21K
Open2.44D1 Closing2.44Amplitude9.62%
Mkt Cap2.71MTradable Cap2.59MTotal Shares1.11M
T/O148.88KT/O Rate5.67%Tradable Shares1.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement
Reuters  ·  02-24 22:06
BRIEF-Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement
Adial Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance
Reuters  ·  02-24 22:01
Adial Pharmaceuticals Regains Nasdaq Minimum Bid Price Compliance
Adial Pharmaceuticals Highlights FDA Shift Toward Single Pivotal Trial Backed by Confirmatory Evidence
Reuters  ·  02-23 21:31
Adial Pharmaceuticals Highlights FDA Shift Toward Single Pivotal Trial Backed by Confirmatory Evidence
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire  ·  02-17
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim
TIPRANKS  ·  02-11
Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim
Adial Pharmaceuticals trading halted, news pending
TIPRANKS  ·  02-06
Adial Pharmaceuticals trading halted, news pending
Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?
TIPRANKS  ·  02-05
Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?
Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance
TIPRANKS  ·  02-05
Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
GlobeNewswire  ·  02-04
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Adial Pharmaceuticals Inc - Announces 1-for-25 Reverse Stock Split
THOMSON REUTERS  ·  02-04
Adial Pharmaceuticals Inc - Announces 1-for-25 Reverse Stock Split
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
GlobeNewswire  ·  02-04
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
GlobeNewswire  ·  01-14
Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
Adial Pharmaceuticals Director James W. Newman Jr. Resigns
Reuters  ·  01-07
Adial Pharmaceuticals Director James W. Newman Jr. Resigns
Adial Pharmaceuticals Inc. Announces Date for Upcoming Special Stockholders Meeting
Reuters  ·  2025-12-24
Adial Pharmaceuticals Inc. Announces Date for Upcoming Special Stockholders Meeting
Adial Pharmaceuticals announces $2.86M warrant inducement transaction
TIPRANKS  ·  2025-11-26
Adial Pharmaceuticals announces $2.86M warrant inducement transaction
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
GlobeNewswire  ·  2025-11-26
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating
TIPRANKS  ·  2025-11-19
Strategic Advancements and Collaborations Propel Adial Pharmaceuticals’ Buy Rating
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  2025-11-17
Calendar of U.S. Earnings Expected in the Week Ahead
Adial Pharmaceuticals reports Q3 net loss of $1.8 million
Reuters  ·  2025-11-14
Adial Pharmaceuticals reports Q3 net loss of $1.8 million
Adial Pharmaceuticals Q3 Net Income USD -1.8 Million
THOMSON REUTERS  ·  2025-11-14
Adial Pharmaceuticals Q3 Net Income USD -1.8 Million

Introduction

Company Name.
Adial Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Issue price:
--